Lapatinib Versus Lapatinib Plus Capecitabine As Second-Line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer (Gc): a Randomized Phase Ii Trial of the Arbeitsgemeinschaft Internistische Onkologie (Aio)

Exploratory biomarker analysis in patients treated with vinorelbine plus everolimus or vinorelbine monotherapy as second-line treatment for HER2-negative advanced breast cancer: Final results from the randomized phase II trial VicTORia

Annals of Oncology ◽

10.1093/annonc/mdy272.285 ◽

2018 ◽

Vol 29 ◽

pp. viii94

Author(s):

T. Decker ◽

A. Mündlein ◽

N. Marschner ◽

A. Welt ◽

T. Riedt ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Breast ◽

Line Treatment ◽

Second Line ◽

Randomized Phase Ii ◽

Biomarker Analysis

1220P A randomized phase II trial of anlotinib plus docetaxel vs docetaxel for second-line treatment of EGFR-negative NSCLC (ALTER-L018)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1825 ◽

2021 ◽

Vol 32 ◽

pp. S970

Author(s):

L. Wu ◽

Z. Wu ◽

Z. Xiao ◽

Z. Ma ◽

J. Weng ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Abituzumab Combined with Cetuximab Plus Irinotecan Versus Cetuximab Plus Irinotecan Alone, as Second-Line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer: The Poseidon Phase I/Randomized Phase II Trial

Annals of Oncology ◽

10.1093/annonc/mdu193.8 ◽

2014 ◽

Vol 25 ◽

pp. ii107

Author(s):

E. Elez ◽

I. Kocáková ◽

T. Höhler ◽

U. Martens ◽

C. Bokemeyer ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Randomized Phase Ii Trial of Hange-Shasin-To Versus Placebo to Prevent Diarrhea in Patients with Metastatic Colorectal Cancer Under Iris+Bev Second-Line Treatment (Hgcsg1301)

Annals of Oncology ◽

10.1093/annonc/mdu356.73 ◽

2014 ◽

Vol 25 ◽

pp. iv541

Author(s):

H. Fukushima ◽

S. Yuki ◽

H. Nakatsumi ◽

H. Hayashi ◽

K. Harada ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

A Randomized Phase II Trial of Oral Topotecan Versus Docetaxel in the Second-Line Treatment of Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.3816/clc.2008.n.023 ◽

2008 ◽

Vol 9 (3) ◽

pp. 154-159 ◽

Cited By ~ 4

Author(s):

Suzanne Jones ◽

Dana Thompson ◽

John Barton ◽

Jeff Patton ◽

Dianna Shipley ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

Oral Topotecan

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

First Line Treatment

172PD Final analysis: Phase II trial of irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer: HGCSG0902. Comparison of administration interval in cetuximab treatment

Annals of Oncology ◽

10.1016/s0923-7534(21)00330-6 ◽

2016 ◽

Vol 27 ◽

pp. ix54

Author(s):

T. Ando ◽

S. Yuki ◽

H. Nakatsumi ◽

T. Muranaka ◽

A. Hosokawa ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Analysis Phase ◽

Administration Interval

Locally Advanced Esophageal Cancer

Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial

Esophagus ◽

10.1007/s10388-021-00831-3 ◽

2021 ◽

Author(s):

Osamu Shiraishi ◽

Tomoki Makino ◽

Makoto Yamasaki ◽

Koji Tanaka ◽

Kotaro Yamashita ◽

...

Keyword(s):

Esophageal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Advanced Esophageal Cancer ◽

Short Term ◽

Randomized Phase Ii ◽

Results of a phase II trial with cystemustine at 90 mg/m2 as a first-or second-line treatment in advanced malignant melanoma

Melanoma Research ◽

10.1097/00008390-199912000-00011 ◽

1999 ◽

Vol 9 (6) ◽

pp. 607-610 ◽

Cited By ~ 10

Author(s):

H. Cure ◽

P. Souteyrand ◽

R. Ouabdesselam ◽

H. Roche ◽

A. Ravaud ◽

...

Keyword(s):

Malignant Melanoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Advanced Malignant Melanoma

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment